KEXING BIOPHARM CO.(SH:688136) Shang Hai Zheng Quan Bao·2026-01-05 00:30Group 1 - The company plans to conduct foreign exchange derivative trading in 2026 to mitigate risks associated with foreign exchange rate and interest rate fluctuations, with a total trading limit not exceeding 75 million RMB or equivalent foreign currency [4][10]. - The trading will primarily utilize the company's own funds and will not involve raised funds [5][6]. - The company will employ simple and transparent foreign exchange derivative instruments, such as forward contracts and options, with a maximum duration of 12 months [6][8]. Group 2 - The company has approved the use of up to 150 million RMB of temporarily idle raised funds for cash management, focusing on safe and liquid investment products with a maturity of no more than 12 months [21][24]. - The investment aims to enhance the efficiency of raised fund usage while ensuring that it does not affect the ongoing projects funded by these raised funds [23][38]. - The company will strictly control risks associated with these investments and will not use the funds for speculative purposes [35][50]. Group 3 - The company plans to provide a maximum guarantee of 320 million RMB for its subsidiaries' bank loans in 2026, which will enhance financing efficiency [53][60]. - The guarantee is based on the current business situation and is expected to be within a controllable risk range [54][61]. - The company has no overdue guarantees or litigation-related guarantees, ensuring a stable financial position [62]. Group 4 - The company anticipates daily related transactions with specific affiliated companies, with a total expected amount not exceeding 18.5 million RMB for 2026 [67][70]. - These transactions are necessary for the company's normal business operations and are conducted at market prices to ensure fairness [75][76]. - The company has established contracts with related parties to ensure compliance and protect shareholder interests [73][74]. Group 5 - The company intends to apply for a financing limit of up to 300 million RMB from banks and financial institutions in 2026, using its own assets as collateral [78][79]. - This financing is aimed at meeting the operational funding needs of the company and its subsidiaries without adversely affecting business operations [80].